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A b s t r a c t  
In this study, Lornoxicam (LX) loaded spermaceti (SC) microspheres were prepared using meltable 
emulsified dispersion cooling induced solidification technique and the bioavailability of the marketed 
product (Flexispaz® capsule-reference-product A) was compared with the optimized formulation 
(lornoxicam loaded spermaceti microspheresătestăproduct B). Morphological studies of wax 
microspheres were evaluated using scanning electron microscopy (SEM). The SEM images showed 
the spherical shape of wax microspheres and more than 97% of the isolated microspheres were in 
the size range 309-317 μm. Differential scanning calorimetry (DSC), Fourier transforms infrared 
(FTIR) spectroscopy and stability studies showed that the drug after encapsulation with SC 
microspheres was stable and compatible. A single dose, randomized, complete cross over study of 
LX (8mg) microspheres were carried out on 10 healthy male and female Albino sheepÊs under 
fasting conditions. Plasma LX concentrations and other pharmacokinetic parameters obtained were 
statistically analyzed. Based on this study, it can be concluded that drug loaded LX microspheres 
and Flexispaz® capsule are bioequivalent in term of the rate and extent of absorption. 
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Introduction 
Lipophilic drugs are poorly water-soluble, but easily mix with waxy 
materials and exhibit good absorption rate[1]. However, reported 
methods are not suitable for all lipophilic drugs2 at its end use and 
recent years different methods have been developed to design 
different types of waxy microspheres loaded with lipophilic drugs 
[2]. From the point of environmental concern and human safety, 
dosage forms should be free from toxic solvents during 
preparation.  In the present study, meltable dispersed emulsified 
cooling induced solidification method was used to prepare wax 
microspheres which are free from toxic solvent. 
LX is a non-steroidal, anti-inflammatory agent with  analgesic 
properties [3]. and chemically as 3Eă6ăchloro-3[hydroxyl( pyrolină
2-2ylamine) methylene) ă2- methyl -2- 3ăhydroă 4H thieno [2,3 ă e] 
[ 1,2] thiazină 4ă one 1,1 dioxide. LX has a molecular weight of 
371.80 g/mol and molecular formula is C13H10ClN304S2 . LX is 
commercially available in the form of conventional immediate-
release tablets (4 and 8 mg), rapid-release tablets (8 mg), and 
parenteral formulations (4 mg/ml) for intravenous and 
intramuscular use. Studies revealed that it is more effective than 10 
mg morphine when used to control pain after oral surgery & its 
analgesic activity is comparable to that of opioids. It is effective in 
the treatment of post-operative pain and rheumatoid arthritis [4]. It 
differs from other oxicams by its potent inhibition of prostaglandin 
biosynthesis [5]. In ischemia and ischemia-reperfusion conditions 
LX has exhibit protective effects on the development of myocardial 
infarction in rats [6] & also demonstrated its protective effects 
against herpetic stromal keratitis [7]. LX should be dosed at least 2 
times a day. Due to its narrow therapeutic index, the frequency of 
adverse effects is dose related [8]. Considering the long 
therapeutic regimen of rheumatoid arthritis therapy, the 
administration of LX may induce adverse effects on gastro 
intestinal tract (GIT), central nervous system (CNS), renal & 
cardiac systems & on the skin. The occurrence of these adverse 
effects can be reduced by the use of controlled release 
formulations. Oral conventional dosage forms are administered 2ă3 
times a day to maintain adequate and effective therapeutic 
concentration in blood.  
Spermaceti (SC) used in the current study has good 
pharmaceutical and biological properties [9]. SC is hard, shiny, oily 
to touch, slightly unctuous with faint odour and mild bland taste 
which makes it very useful excipient in cosmetics and 
pharmaceuticals. SC is non-toxic, non-irritant, non-immunogenic, 
biodegradable, biocompatible, gastro resistant, high carrier 
capacity, low production costs, reproducible properties used for 
drug entrapment and its release in a controlled manner. SC is used 
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widely used as a coating agent, stiffening agent, emollient, 
emulsifying agent in pharmaceuticals and cosmetics. It is included 
in the FDA as inactive ingredient in non-parenteral medicines 
licensed in the UK [10]. 
By employing suitable modification in the manufacturing process, 
controlled release formulation of LX has been developed which has 
several advantages over other conventional dosage forms such as 
reduction in the side effects & adjusting the absorption rate[11]. 
Recent reports showed that biocompatible, biodegradable, non-
immunogenic waxes were successfully used for the encapsulating 
lipophilic drug and control the drug release in the intestinal tract 
[12]. SC is gastro resistant, but susceptible to intestinal juice 
[13].Without the risk of side effects, desired plasma levels can be 
achieved using once a day dose of controlled release preparation 
[14] & it is an effective route to suppress the toxicity of LX.  The 
aim of the present study was to prepare the wax microspheres, 
compared the in vitro release of LX from wax microspheres with 
commercially available oral formulation Flexispaz® (8 mg capsule) 
and to carry out the bioavailability of two different oral LX 
formulation (optimized microsphere formulation and 
Flexispaz®8mg capsule) following single dose in healthy Albino 
sheepÊs to show the bioequivalence between both oral formulation.  
Materials and Methods 
Materials 
Lornoxicam (LX), pure drug and Tenoxicam (TX), the internal 
standard were kindly donated by Micro Labs (Bangalore, India). LX 
is an odorless, yellow crystalline substance, practically insoluble in 
water and sparingly soluble in alcohol. LX has a pKa of 4.5 and is 
stable in neutral or slightly acidic media and decomposes in strong 
alkali. It has a melting point between 226 and 228ĈC and has 
molecular weight of 371.82. Spermaceti wax, Tween 80 and all 
other chemicals and solvents used were of analytical grade and 
purchased from Ranbaxy Fine chemicals (New Delhi, India). 
Commercially available oral capsule formulation (Flexispaz® 8mg, 
Glenmark, India) is used for the present study.  
Preparation of microspheres 
Disperse 1 part of LX (passed through sieve No. 100) in the melted 
3 parts of SC and stirred to obtain a homogeneous mixture. To the 
mixture transferred 200 ml of Phosphate buffer solution (pH 6.3), 
previously maintained at a temperature higher than melting point of 
LX. The melted mixture was stirred for 5 min at 800 rpm by adding 
surfactant, Tween 80 (0.3 % w/w). Rapid cooling of the developed 
reaction mixture to 100C produces floated spherical particles. 
Collect the separated solid spheres by filtration and remove 
surfactant traces from wax spheres by washing with stream of 
water. Dry the free flowing microspheres at room temperature for 
two day. Set of five formulations were prepared presented in 
Table1. 
 
 
 
 
 
Table 1. Formulations chart 
 
Formulation 
Code 
Drug (gm) Spermaceti (gm)
A1 2.8 8.8
A2 2.9 8.9
A3 3.0 9.0
A4 3.1 9.1
A5 3.2 9.2
 
Characterization of microsphere 
Tap density, Angle of repose (h), Percent yield, & CarrÊs index (% I) 
of the prepared SC microspheres was determined. 
Scanning electron microscopic studies and sphericity 
determination  
Scanning electron microscope (SEM) photomicrographs were 
recorded using Joel-LV-5600 SEM, USA. Sphericity of the wax 
microsphere was determined using a digital camera (Sony, DSC T-
4010.Cyber shot, Japan. Photomicrographs were taken) & mean 
Feret diameter (FD), Aspect ratio (AR) and two-dimensional shape 
factor (eR) were calculated.  
Differential scanning calorimetry (DSC) 
All dynamic DSC studies were carried out on DuPont thermal 
analyzer with 2010 DSC module & instrument was calibrated using 
high purity indium metal as standard. Triplicate scans were taken in 
nitrogen atmosphere at the heating rate of 10ĈC/min. 
Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectra of pure drug, empty microspheres and drug 
encapsulated microspheres were taken using FTIR 
spectrophotometer (Shimadzu, Model 8033, USA) in the wave 
number region between 4000- 400 cm -1). 
Estimation of drug loading 
From each batch, drug loaded microspheres were selected & 
powdered in a mortar. Extract the drug from wax microspheres 
using methanol, filtered and analyzed for drug content after 
suitable dilution by HPLC[15]. 
In Vitro studies 
In vitro release study of drug loaded microspheres was carried out 
USP XXI dissolution apparatus, type II. The prepared formulations 
were subjected for dissolution study in 900ml dissolution   medium 
for 2 h in pH 1.2 hydrochloric acid buffer and 8 h in pH 7.2 
phosphate buffers. 10 ml of sample solution was withdrawn 
periodically using guarded sample collectors at an interval of 30 
min for first 4 h and at 60 min interval for the next 6 h.    
Gowda et al. International Journal of Drug Delivery 6 (1) 07-13 [2014] 
 
PAGE | 9 |
 
 
In vivo studies  
The study was an open, randomized complete cross over design in 
which 8 mg dose of LX (Flexispaz® capsule and formulation A3) 
was administered to sheepÊs (wash out period of 2 weeks). The 
content uniformity of marketed product and optimized formulation 
has been estimated. Ten adult albino sheepÊs (age 5 to 7 years & 
weight 25 and 28 kg) employed for in vivo studies. The in vivo 
experimental protocol was approved by the institutional animal 
ethical committee, JSS Medical College Hospital and J.S.S College 
of Pharmacy, Mysore, Karnataka, India. The written information on 
the study was provided to the Veterinary Surgeon, Central Animal 
Facility, JSS Medical College Hospital. The drug content was 
determined by extracting the drug from their respective dosage 
forms using methanol (80%). Animals have been shifted to the 
clinical trial laboratory and 18 gauge (1.3X45 mm, 96ml/min) 
canula was inserted in to a jugular vein with heparinised saline lock 
for ensuing blood sample (5ml). Flexispaz® capsule and 
formulation A3 (Test medications) were administered to the sheepÊs 
and blood samples were collected at 0 h (pre dose interval) and at 
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10 post dose intervals. The 
plasma was collected from blood samples by centrifugation (eltek-
TC 4100 D centrifuge, Mnf. by Elektroshaft, Bombay, India) at 1500 
rpm for 10 min. The collected plasma was stored at ă20oC prior to 
analysis. Plasma concentration of drug from the collected samples 
was quantified by HPLC method. 
Chromatographic Studies 
The HPLC system consisted of HPLC-Shimadzu (Tokyo, Japan) 
LC-6A model, fitted with a μ ăBondapack C18 (4.6 X 250 mm) 
column of particle size 5μm (Supelco, Bellefonte, PA). The flow 
rate was adjusted to 1μL/min and the drug concentration was 
detected using a UV/visible detector (SPD- 6Av). Tenoxicam (TX) 
was used as internal standard. The mobile phase consisted of 
65:35 (% v/v) mixture of 5M ammonium acetate and acetonitrile 
with final pH adjusted to 5 with glacial acetic acid. The column was 
equilibrated for 30 min with mobile phase before injection and 
detection was carried out at wavelength of 372nm. Quantification 
was achieved by the measurement of the peak area ratio of the LX 
to the internal standard (TX). The limit of detection of LX in plasma 
was 100 ng/ml (500 μL of plasma injected). 
Pharmacokinetics and Statistical data evaluation 
The pharmacokinetic parameters were calculated using the Quick 
calk, computer PK calculation programme. The maximum plasma 
concentration (Cmax) & time required to achieve maximum plasma 
concentration (Tmax) were calculated directly from plasma level 
profile and the elimination rate constant (Kel) was calculated by the 
method of least square regression analysis.  The area under the 
curve from 0 to 24h (AUC0ă24) was calculated using trapezoidal 
rule method. The drug plasma concentration and pharmacokinetic 
parameters were analyzed by paired t- test and analysis of 
variance (ANOVA) at 95% confidence limit. Difference between two 
related means was considered statistically significant when their P 
values were equal to or less than 0.05. 
Results and Discussion 
Waxes exhibit stable physical properties and behavior suitable to 
develop microspheres (biodegradable, gastro resistant, 
biocompatible) which sufficiently release the encapsulated drug in 
the intestinal lumen [17]. The present study employed the modified 
novel meltable dispersion emulsified cooling induced solidification 
method to prepared LX loaded microspheres using inert wax (SC) 
as carrier. The influence of various parameters on the prepared 
microspheres were analyzed and mentioned. The maximum drug 
was loaded in the microspheres at pH 4.0. If the pH was increased 
from 4.2 to 7.0, the percentage of LX loading was reduced from 
23.22 to 4.98 %. 150 ml of aqueous phase was suitable to prepare 
spherical microspheres. It was observed that as the volume of 
aqueous phase increased, it affects the morphology and yield of 
the microspheres. The spherical and free flowing microspheres 
were produced using an optimum 1:3 w/w ratio of drug to wax (SC) 
(Table 1). It was also noticed that as drug to wax ratio was 
increased (2:3 w/w), clumps of microspheres were produced at the 
time cooling. SEM photographs also showed the development of 
drug crystal on the surface of microspheres [18]. 
Encapsulation of LX into SC microspheres requires the addition of 
surfactant (Tween 80) at an optimum concentration of 0.4% w/w for 
the proper distribution of lipophilic SC in hydrophilic aqueous 
phase. The temperature of the aqueous phase was maintained at 
50C higher than the melting point of the SC in the corresponding 
formulations. It was observed that the resultant microspheres were 
free from surface irregularities, except some wrinkles. When the 
temperature of the aqueous phase was less than 50C than the 
melting point of the SC, big flakes were noticed. Average size of 
the produced microspheres was in the range between 309 to 317 
mm presented in Table 2. Optimum Stirring speed (900 rpm) and 
stirring time (5 min) produces better size of the microspheres.  
The micromeritic properties of the prepared microspheres are 
summarized in Table 2.The obtained data for angle of repose, 
tapped density and % CarrÊs indexes were well within the range, 
indicates good flow potential for the prepared microspheres. SEM 
micro photographs showed that the prepared microspheres were 
spherical in nature, containing inward dents and absence of drug 
crystals on the surface as shown in Figure.1. The microspheres 
were dried at room temperature for 24h, showed the sphericity 
value nearer to 1. However, microspheres dried for 24h at 400C 
exhibits the sphericity value more than 1. DSC thermograms, 
Figure.2 showed a sharp endothermic peak at 227.80C & 226.70C 
for pure LX & LX loaded formulation A3, respectively.     From the 
above study it was confirmed that the loaded LX was uniformly 
distributed on the wall of the microspheres [19]. 
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      Table 2. Micromeritic properties of the drug loaded SC microspheres   
Formulation 
Code 
Average size 
(øm) Meanμ 
SD* 
Yield (%) 
Mean μ 
SD* 
Angle of 
repose  (θ0) 
Mean μ SD* 
CarrÊs
Index (%)       
Mean μ SD* 
Tapped  Density 
(g/cm3) 
Mean μ SD* 
A1 309 μ 03 92.32 μ 0.8 24.12μ 0.9 9.21 μ 0.6 0.39 μ 0.2 
A2 312μ 06 93.43μ 1.1 26.34μ 1.1 10.12 μ 0.5 0.45 μ 0.4 
A3 313μ 04 95.79μ 0.7 27.15μ 1.2 12.54 μ 0.8 0.58 μ 0.3 
A4 315μ 02 91.23μ 1.3 25.28μ 1.0 11.89 μ 0.4 0.35 μ 0.5 
A5 317μ 05 89.10μ 1.1 23.14μ 0.8 10.58 μ 0.3 0.32 μ 0.3 
   
  *Standard deviation n = 3 
 
 
 
        Figure. 1. SEM microphotographs of drug loaded microspheres formulation (A3)  
 
  Fighre. 2. DSC thermograms of pure Lornoxicam and Lornoxicam loaded spermaceti  microspheres   (Formulation A3)  
 
Figuge. 3 showed the FTIR spectra of LX and compare it with the 
formulation A3 at 3,090 cmî1 (NH stretching), 1,642 cmî1(C=O 
stretching), 1,597 and 1,559 cmî1 (NăH group stretching), 1,157, 
1,387, and 1,336 cmî1 (O=S=O group stretching), 827.94 cmî1 (ă
CH aromatic ring bending) and 766.8 cmî1 (CăCl vibration 
bending). The characteristic IR absorption peaks of LX were not 
altered after successful encapsulation of drug, indicating no 
chemical interactions between the drug and used excipients [20]. 
 
 
The XRD pattern of LX and formulation A3 is shown in Figure. 4. It 
was observed that pure drug exhibits several sharp high-intensity 
peaks at diffraction angles 2θ of 7.8Ĉ, 10.2Ĉ, 12.2Ĉ, 14.5Ĉ, 18.2Ĉ, 
22.2Ĉ, and 24.5Ĉ suggesting that LX existed as a crystalline 
material. A slight decrease in LX crystalline character was 
observed in the diffractograms of the formulation A3 as evidenced 
by the noticeable decrease in the number and intensities of peaks 
present in their X-ray diffractogram when compared to the 
corresponding pure LX [21].  
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                Figure-3.FTIR spectra of Lornoxicam and Lornoxicam loaded spermaceti microspheres(Formulation A3)  
 
              Figure. 4. XRD pattern of Lornoxicam and Lornoxicam loaded spermaceti microspheres (Formulation A3)  
 
The percentage of drug loading in the formulations was found to be 
in the range of 19.67 to 23.22 %. The drug loading capacity was 
maximum in the formulation A3 (23.22) whereas minimum drug 
was loaded in the formulation A4 (19.67). Drug encapsulation 
efficiency (%) was found to be more for formulation A3 (95.23%) as 
compared to A1 (90.32%), A2 (92.13%), A4 (88.23%), A5 (89.98%).  
No significant amount of drug was released from the microspheres 
at gastric pH, indicates spermaceti is gastro resistant in nature. 
The data obtained from in vitro study revealed that at the end of 
12th h the drug release from the optimized formulation A3 (96.41%) 
was slower than Flexispaz® capsule (98.57%) in the intestinal 
environment. The influence of hydrophobic nature and molecular 
weight of spermaceti during drug release was observed. 
The optimized formulation A3 and Flexispaz® capsule were kept 
for stability studies at 25 ÀC/ 60% RH (Relative humidity), 30 ÀC/ 
65% RH and 40 ÀC/ 75% RH for a period of 90 days. It was 
observed that in vitro drug release from Flexispaz® capsule and 
formulation A3 at the end of 90 days (12th h), were 98.43 and 96.32 
%, respectively. From the release studies, it was observed that, 
there was no significant change in in vitro drug release from both 
the products, indicates good stability for the prepared formulation. 
The drug content uniformity for Flexispaz®8 mg capsule and 
formulation A3 was found to be 7.95 mg & 7.90 mg, respectively. 
The percent of drug content uniformity of Flexispaz®8 mg capsule 
and formulation A3 are 99.76 and 99.49%, respectively. 
The mean plasma concentration as a function of time is shown in 
Figure.5 and the calculated pharmacokinetic parameters of 
Flexispaz® and A3 formulation are given in Table 3. After oral 
administration of both the products, more mean Cmax value was 
observed for Flexispaz®8 mg capsule than formulation A3 and 
difference in the Cmax values obtained for both the formulations 
was statistically insignificant. On the basis of the therapeutic 
concentration range of LX, the therapeutic effects of both 
formulations would be probably be maintained for about 12 h 
following a single dose administration. In the present study, both 
controlled release formulations are associated with a similar onset 
of therapeutic response, following a single dose administration 
under fasting conditions [22]. 
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Table 3. Comparison of mean values of pharmacokinetics obtained for products Flexispaz®& formulation A3      
Parameters Flexispaz® Formulation A3 P value 
Tmax  ( h ) * 2.29 2.15 < 0.05 
Cmax  (ng /ml) *  914 μ 13.12 889 μ 10.30 < 0.05 
T1/2 (  h-1 ) * 4.2 μ 0.12 4.1 μ 0.10 < 0.05 
U C0-24*(ng/ml h-1)    4654 μ 56.12 4213 μ 46.30 < 0.05 
AUC0-¥*(ng/ml h-1)    4889 μ 65.21  4745 μ 57.38 < 0.05 
       *Standard deviation n = 3  
 
 
 Figure. 5. Mean plasma concentrationsătime profile of lornoxicam from Flexispaz® and formulation A3.                                     
 
The time taken to reach maximum plasma concentration Tmax of 
LX was little higher in case of Flexispaz® compared to formulation 
A3. However, no statistical significant differences were observed 
between two products. The calculated mean T1/2 values for 
Flexispaz® and formulation A3 were 4.2 μ 0.12 hî1 and 4.1 μ 0.10 
hî1, respectively & no statistical significance differences were 
observed between both the products23. From the study it was 
noticed that a small difference was observed between both 
products related to Cmax, Tmax, T1/2, and reduced fluctuations (peak 
to trough ratios) of the plasma concentrations. 
The mean AUC0ă24 values for Flexispaz® and formulation A3 were 
4654 μ 56.12 ng/ml h -1 and 4213 μ 46.30 ng/ml hî1  respectively 
and decreased AUC values from both products may be due to slow 
in vitro release of LX  when compared with conventional dosage 
forms24. The average value of the individual and mean AUC 0ă24 
ratio at 95% confidence limit (0.8 ă 1.24) was within acceptable 
limits for bioequivalent products. The observed mean AUC 0- ¥ 
values for Flexispaz® and formulation A3 was 4889 μ 65.21 
ng/ml.h-1 and 4745 μ 57.38 ng/ml.h-1 does not show any significant 
statistical difference between these products. In order to obtain in 
vitro-in vivo correlation, drug absorption profiles were compared for 
Flexispaz® and formulation A3 using the cumulative fraction of the 
drug absorbed in vivo against cumulative fraction of the drug 
dissolved in vitro up to 12 h. Both products showed an adequate 
correlation & pharmacokinetic parameters clearly indicate that the 
parameters of formulation A3 are in good agreement with 
Flexispaz®. The products Flexispaz® and formulation A3 studied in 
the present study were found to be bioequivalent. 
Conclusions 
The objective of the present study was to prepare and evaluate 
wax microspheres of SC loaded with LX by optimized meltable 
dispersion emulsified cooling induced solidification method for 
controlled release. The method employed was simple, rapid, and 
economical and does not imply the use of toxic organic solvents. 
The results of the drug entrapment and micromeritic properties, 
exhibited fairly good spherical nature as evidenced by SEM 
photomicrograph. The compatible state of the drug loaded wax 
microspheres were evaluated by FTIR and DSC. Both the 
formulations were found to be bioequivalent and showed an 
adequate correlation between cumulative fractions dissolved in 
vitro and cumulative fractions absorbed in vivo. Optimized 
formulation A3 and marketed product Flexispaz® showed similarity 
in drug release profiles and in vivo bioequivalent behavior. From 
the present work, it can be concluded that the prepared wax 
microspheres demonstrate the potential use of SC for the 
development of controlled drug delivery systems for water insoluble 
or lipophilic drug.. 
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